1/7
08:35 am
lxeo
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
07:30 am
lxeo
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/19
07:13 am
lxeo
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer [Yahoo! Finance]
12/19
07:00 am
lxeo
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Medium
Report
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
11/28
05:42 am
lxeo
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics [Yahoo! Finance]
Medium
Report
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics [Yahoo! Finance]
11/18
06:26 am
lxeo
How decentralisation can fill the gaps in Alzheimer's research [Yahoo! Finance]
High
Report
How decentralisation can fill the gaps in Alzheimer's research [Yahoo! Finance]
11/14
08:15 am
lxeo
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at HC Wainwright from $21.00 to $23.00. They now have a "buy" rating on the stock.
Low
Report
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at HC Wainwright from $21.00 to $23.00. They now have a "buy" rating on the stock.
11/13
05:47 pm
lxeo
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at Chardan Capital from $23.00 to $25.00. They now have a "buy" rating on the stock.
Low
Report
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target raised by analysts at Chardan Capital from $23.00 to $25.00. They now have a "buy" rating on the stock.
11/13
01:46 pm
lxeo
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at Leerink Partners from $20.00 to $19.00. They now have an "outperform" rating on the stock.
Medium
Report
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its price target lowered by analysts at Leerink Partners from $20.00 to $19.00. They now have an "outperform" rating on the stock.
11/13
11:12 am
lxeo
Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24 [Seeking Alpha]
High
Report
Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24 [Seeking Alpha]
11/13
07:30 am
lxeo
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Low
Report
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
10/31
08:35 am
lxeo
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
10/30
06:14 am
lxeo
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
High
Report
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
10/25
03:39 pm
lxeo
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $23.00 price target on the stock.
Low
Report
Lexeo Therapeutics, Inc. (NASDAQ: LXEO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $23.00 price target on the stock.
10/22
07:30 am
lxeo
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
Medium
Report
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference